VTVT NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

vTv Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 30.73 USD
-6.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -11.4% below the Trend Line and sits at 55.8% of its 52-week range. The latest completed week returned -6.5%, after a -12.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: earnings are due in 13d.

Setup score 38 out of 100
Latest Close 30.73 USD 24 Jul 2026
1W Return -6.5% latest completed week
4W Return -12.4% short-term follow-through
12W Return -3.0% quarterly tape
Trend Breadth 63.5% 33 of 52 weeks active
Volume Ratio 2.1x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -6.5% Latest completed week; four-week move -12.4%. Indicator stack 35/34 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 52/100 56 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -11.4% below the Trend Line and sits at 55.8% of its 52-week range. The latest completed week returned -6.5%, after a -12.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2912-week average 0.43

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.29Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -12.4% over four weeks, -3.0% over 12 weeks, and 97.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-6.5%
4W-12.4%
12W-3.0%
26W-9.9%
52W97.7%
Active trend streak0 weeks
Active weeks in one year33
Trend breadth63.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.92Latest activity-pressure read.
Pressure change4.9%Four-week change in activity pressure.
Leadership-5.42Latest relative-leadership reading.
RS change-170.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength26/100Blend of value, momentum, and quality. Underlying universe rank 75; rank 1 is best.
Value28/100Relative valuation strength. Underlying universe rank 73; rank 1 is best.
Quality5/100Profitability and accounting quality. Underlying universe rank 96; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth36/100Revenue and earnings growth. Underlying universe rank 65; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
53.7x
Price divided by trailing earnings.
Price / sales
3.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-44.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-0.0%
Gross profit retained from each unit of revenue.
Operating margin
-2.0%
Operating profit retained from revenue.
Free-cash-flow margin
-28.3%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-64.0%
Net share repurchases relative to market value.
Shareholder yield
-64.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
136.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 56 relevant articles.

13 positive · 39 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-30.2%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+16.7%Week of 13 Feb.
Worst week-18.0%Week of 6 Feb.
Latest week-6.5%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses6
Sharp losses7
Recent vol5.9%13-week weekly-return volatility.
Base vol9.0%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -6.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape39/100

Trend, activity pressure, participation, and risk combine to a 39/100 tape read.

 Indicator analysis32/100

Latest 12-week confirmation: trend 2/12, activity pressure 0/12, relative leadership 9/12.

Activity pressure 0.29; No reversal markers Factors35/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 98; Small Cap Core rank 82 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 56 relevant articles.

vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk Insiders5 / 0

5 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202630.73 USD-6.5%34.69 USD21.34 USD-0.92-5.42580.4KOff
17 Jul 202632.88 USD-1.8%34.93 USD21.32 USD-0.740.29417.6KOff
10 Jul 202633.49 USD-5.4%35.04 USD21.30 USD-0.68-1.41273.9KOff
3 Jul 202635.40 USD0.9%35.07 USD21.27 USD-0.736.78285.1KOff
26 Jun 202635.08 USD0.1%34.81 USD21.22 USD-0.977.72320.8KOff
19 Jun 202635.04 USD6.9%34.53 USD21.19 USD-1.153.76265.1KOff
12 Jun 202632.77 USD1.9%34.34 USD21.16 USD-1.270.37137.3KOff
5 Jun 202632.14 USD-3.6%34.28 USD21.16 USD-1.051.42182.8KOff
29 May 202633.35 USD-3.1%34.07 USD21.16 USD-1.071.14154.5KOff
22 May 202634.41 USD-3.6%33.69 USD21.16 USD-1.058.03250.9KOff
15 May 202635.70 USD16.3%33.24 USD21.15 USD-0.9914.08283.3KOn
8 May 202630.68 USD-3.2%32.72 USD21.16 USD-0.94-1.84124.2KOn
1 May 202631.68 USD-3.3%32.43 USD21.18 USD-0.606.96326.0KOn
24 Apr 202632.76 USD-14.1%32.18 USD21.17 USD-0.3312.35440.7KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.